Standard 3D IMRT treatment plans were created for 10 NSCLC patients with lymph node involvement based on the mid-ventilation phase with a prescribed dose of 66Gy/33F. A CTV margin of 1 cm was used around the lymph nodes and was adjusted in order to exclude bone tissue and larger blood vessels. Patient-specific PTV margins of 0.7-1.0 cm were calculated using a probabilistic margin formula and were applied to the CTV. Random day-to-day variations of the baseline shift between the primary tumour and the CTV-node were simulated by blurring the dose distribution in either the cranial-caudal (CC), left-right (LR) or anterior-posterior (AP) directions with a Gaussian error distribution. Furthermore, a systematic shift between the lymph node and the primary tumour was simulated by displacing the dose distribution relative to the delineated structures with both 0.25 cm and 0.50 cm. Sufficient dose coverage of the involved lymph node was defined as the minimum dose (D 98% ) of the CTV-node was larger than 95% of the prescribed dose for 90% of the patients. Results: The figure shows the minimum dose of the CTV-node for 90% of the patients as a function of the random peak-to-peak variation in the CC direction for the different types of simulations. Dose coverage was sufficient for all data points above 95% of the prescribed dose, which is indicated by the dashed line in the figure. Table 1 summarises the acceptable random peak-to-peak variations in the CC, LR, and AP directions with 0 cm, 0.25 cm and 0.50 cm systematic shifts.
of the patient position adjustment based on the online matching of two orthogonal kV fields was investigated. Materials and Methods: Twenty breast cancer patients and 20 patients treated for breast cancer in combination with internal mammary-medial supraclavicular (IMMS) lymph node irradiation, i.e. locoregional breast treatment, were included in the study. Each treatment was performed on a Varian Clinac 2100C/D linear accelerator equipped with an amorphous-silicon EPID and an OBI system (Varian Medical Systems, Inc.) . The patient positioning and isocenter shift were checked with online paired kV-kV matching using the ribs close to the isocenter. One of the orthogonal kV fields was parallel to one of the tangential field directions (see figure) . Only translations were adjusted. The new patient position was verified during 5 fractions by MV imaging of both tangential breast fields and kV imaging of the MS-field. All images were matched in Offline Review (Varian Medical Systems, Inc.) using bony anatomy. The differences for each tangential field were reported as ΔCLD (Central-Lung-Distance, i.e. the distance between the deep field edge and the interior chest wall at field central axis), and ΔC(ranio)C(audal). The differences for the MS-field were reported as ΔVrt, i.e. ΔVertical, ΔCC and ΔLat(eral). The range of the patient mean errors, the percentage of the patient population with an absolute value of the mean error larger than 2mm, the population mean, population systematic error and population random error were reported. Results: For breast cancer treatment with and without IMMS irradiation, a mean CLD error ranging from -1mm to 2mm and from -1mm to 3mm, respectively, was found. Only 5% of the breast cancer patients had a mean ΔCLD > 2mm. The patient mean ΔCC ranged from -3mm to 3mm and from 0mm to 3mm for the breast treatments and the locoregional breast treatments, respectively. For 10% of the patients, the mean ΔCC was larger than 2mm, irrespective of the treatment. None of the population systematic errors were larger than 1mm and none of the population random errors were larger than 2mm, irrespective of the patient group (see table) . The population systematic and random errors measured in the MS-field were smaller than 1mm for all three directions (see table) .
Conclusions:
The new position verification protocol is appropriate for accurate, uniform and quick 3D position verification in non-gated (locoregional) breast radiotherapy and easily extendible to gated breast radiotherapy. An important property of the protocol is the low imaging dose to both the target volume and the healthy tissue thanks to the combination of the kV imaging and the field orientation.
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Purpose/Objective: Uncertainties in patient positioning are a crucial issue to be considered when treating patients with particles. In this study we aim to quantify the effect of small patient misalignment for different proton dose delivery techniques. Materials and Methods: We have investigatedthree different delivery techniques: 3D spot-scanning (3DSS), distal edge tracking(DET) and
2nd ESTRO Forum 2013 S325 isocentric rotational delivery (DIR) where the gantry moves to multiple positions and delivers a ray of spots with various energies from each fixed gantry position without lateral beam scanning. A cylindrical water phantom with a cylindrical target (3.3cm length, 5cm diameter) in the middle of the phantom has been chosen. For 3DSS also a lung tumour patient case has been evaluated. For both cases a dose of 60Gy was prescribed to the CTV in a single fraction. Spot positions and weights were derived and the dose was recalculated with a dose calculation algorithm. For each delivery method and case two plans were derived: one with the isocenter (IC) positioned in the middle of a CT-voxel andone with the IC shifted by 0.4 (0.3)mm (CT grid: Δx=Δy=Δz=1mm) for the cylinder phantom (patient) relative to the IC in each direction simulating a small setup error. Results: Table 1 summarizes the minimal doses to 1%, 50% and 95% of the target. The most robust method shows to be the 3DSS. Particularly for the water phantom the dose differences are minor. However, this is not valid for the patient case. Here, even with 3DSS the minimal dose to 95% of the volume was reduced by almost 3Gy due to the IC shift. Furthermore, local dose differences up to almost 8% within the target and 3mm distant (cc direction) to the IC were found. Generally, the dose differences between the two plans are most obvious within the gradient region. The DET methodis less robust. The general trend is the same as for the 3DSS case but absolute local differences are up to almost 5Gy at 14mm distant from the IC slice. With this technique the dose differences are mainly in the gradient region of the dose distribution. The DIR method is most sensitive to the setup-errors, where the beam rotates around the IC without lateral scanning. The IC shift therefore shifts the dose distribution in the same direction for all beams. Therefore, the detrimental effects can accumulate. Dose differences for the two plans are up to 7% even within the IC slice.
Conclusions:
The results show that even very small setup errors that cannot be completely avoided through image guidance can influence the resulting dose distributions depending on the delivery method for proton therapy. However, the presented results assume a single fraction delivery which is not the usual clinical practice but illustrates the effect best. For fractionated treatment the effects should be reduced, however, based on the presented results, studies evaluating the residual effects with particular respect to the applied delivery technique are required. Purpose/Objective: IMRT and VMAT for RT of pancreatic cancer can reduce toxicity to OARs such as stomach, small intestines and kidneys, but the tight conformity of the high-dose surface to the target area in these techniques requires highly accurate positioning. Daily conebeam CT (CBCT) enables pretreatment correction of patient setup errors. The pancreas shows considerable day-to-day positional variation relative to the vertebrae, which can introduce substantial systematic and random setup errors. The use of intratumoral fiducial markers, visible on CBCT, can help reduce the setup errors and decrease the currently large PTV. The aim of our study is to quantify interfractional variation in tumor position using fiducials and CBCT and thus determine the potential benefit of using intratumoral fiducials rather than bony anatomy for daily pancreatic patient setup verification.
PO-0852 Interfractional variation in position of pancreatic tumors measured with daily CBCT using fiducial markers

Materials and Methods:
Eleven consecutive pancreatic cancer patients were included in our study and each received 2 to 3 gold fiducial markers (Visicoil; 0.35 mm diameter) by endoscopic ultrasound-guided implantation. The two markers of one patient could later not be located on the reference CT. In the other 10 patients, a total of 25 markers were visible on the CT as well as on all CBCTs. For these patients, who received 25 × 2Gy, a total of 242 CBCTs were registered with the reference CT on bony anatomy and on each of the markers. From this, the displacement of markers relative to the vertebrae was determined, as well as the distance between marker pairs. Marker migration, tissue deformation and marker localization error all affect the distance between two markers. To validate the use of the fiducial markers as indicator of tumor position, we analyzed the 20 marker pair distances using linear fits to the CBCT data. Results: Pair distances showed only slight trends (mean slope of -0.03 mm/day, range -0.10 to 0.02 mm/day, 5/20 with p<0.05), most likely due to tissue deformation (shrinkage), but no clear shifts that would indicate marker migration. The residuals of the linear fits had a mean SD of 0.8 mm (range 0.4-1.3 mm), a measure for localization error. From the positional variation, we found for these ten patients an SD of systematic error Σ of 4.0, 5.3 and 3.6 mm and an SD of random error σ of 3.6, 4.9, and 2.3 mm, in LR, SI and AP, respectively. See the Figure for the distributions in the SI-direction.
For 11% (26/242) of fractions, the vector displacement relative to bony anatomy was >15mm; 29% (69/242) showed a vector displacement >10mm. For one patient the vector displacement for 72% (18/25) of fractions was >10mm. Conclusions: This study of interfractional variation of pancreatic tumor position shows large mean displacements (systematic errors) in addition to a wide spread in positional range between patients. This strongly supports the benefit of on-line position verification based on the tumor itself rather than on bony anatomy, and hence the necessity of implantation of intratumoral fiducial markers.
